Gene: ANO3

63982
C11orf25|DYT23|DYT24|GENX-3947|TMEM16C
anoctamin 3
protein-coding
11p14.3-p14.2
Ensembl:ENSG00000134343 MIM:610110 Vega:OTTHUMG00000166096 UniprotKB:Q9BYT9
NG_042856.1
SNP Mapped
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.947e-1 (AD)  3.492e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs11029525chr11:26334327 (GRCh38.p7)A>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CACNA1E0.934
GABRA40.929
AKAP50.926
DGKB0.922
CAMK40.921
CNKSR20.917
ST8SIA30.917
KCNA40.916
DRD10.914
GABRB30.914

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MYL3-0.609
CSAG1-0.593
RAB13-0.561
TFPI2-0.559
CNN2-0.557
FLT3LG-0.547
RNF135-0.545
WWTR1-0.544
EMP3-0.54
CMTM3-0.538

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANO3 mRNA"25510870
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of ANO3 mRNA"19114083
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANO3 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANO3 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANO3 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANO3 mRNA"25510870
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of ANO3 mRNA"28973690
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of ANO3 mRNA29067470
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of ANO3 mRNA22100608
D000535Aluminum[APP protein modified form binds to Aluminum] which results in decreased expression of ANO3 mRNA21298039
D000639AmitriptylineAmitriptyline results in decreased expression of ANO3 mRNA22341215
C006632arsenic trioxidearsenic trioxide results in decreased expression of ANO3 mRNA26705709
D001280AtrazineAtrazine results in decreased expression of ANO3 mRNA25929836
C547126AZM551248AZM551248 results in decreased expression of ANO3 mRNA22323515
C487081belinostatbelinostat results in increased expression of ANO3 mRNA26272509
C487081belinostat"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA"27188386
C006780bisphenol Abisphenol A results in decreased expression of ANO3 mRNA25181051
D003630DaunorubicinANO3 affects the susceptibility to Daunorubicin17545624
D016047Zalcitabine"[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of ANO3 mRNA"18606552
D013759DronabinolDronabinol results in increased expression of ANO3 mRNA21955143
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of ANO3 mRNA]27941970
D003976DiazinonDiazinon results in increased expression of ANO3 mRNA29108742
D003999Dichloroacetic AcidDichloroacetic Acid results in increased expression of ANO3 mRNA28962523
C118739entinostatentinostat results in increased expression of ANO3 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA"27188386
D000431EthanolEthanol results in increased expression of ANO3 mRNA21955143
D005473FluoxetineFluoxetine results in decreased expression of ANO3 mRNA17033635
D005557FormaldehydeFormaldehyde results in increased expression of ANO3 mRNA23649840
C514793gp120 protein, Human immunodeficiency virus 1"[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of ANO3 mRNA"18606552
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ANO3 mRNA25613284
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of ANO3 mRNA26752646
C008261lead acetatelead acetate affects the expression of ANO3 mRNA21147602
D009020MorphineMorphine results in increased expression of ANO3 mRNA21955143
D009538NicotineNicotine results in decreased expression of ANO3 mRNA21955143
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA"27188386
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANO3 mRNA"25510870
D011441PropylthiouracilPropylthiouracil results in decreased expression of ANO3 mRNA24780913
C513428pyrachlostrobinpyrachlostrobin results in increased expression of ANO3 mRNA27029645
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of ANO3 mRNA23806026
D012999SomanSoman results in decreased expression of ANO3 mRNA19281266
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ANO3 mRNA25613284
D014212TretinoinTretinoin results in decreased expression of ANO3 mRNA23724009
C012589trichostatin Atrichostatin A results in increased expression of ANO3 mRNA24935251
D014520UrethaneUrethane results in decreased expression of ANO3 mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of ANO3 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of ANO3 mRNA23179753|2438349
C025643vinclozolinvinclozolin affects the expression of ANO3 mRNA19015723
C111237vorinostatvorinostat results in increased expression of ANO3 mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005229intracellular calcium activated chloride channel activityNOTIDA21984732  
GO:0005229intracellular calcium activated chloride channel activity-TAS-  
GO:0017128phospholipid scramblase activity-IEA-  
GO:0046983protein dimerization activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006869lipid transport-IEA-  
GO:0016048detection of temperature stimulus-IEA-  
GO:0034220ion transmembrane transport-TAS-  
GO:0050982detection of mechanical stimulus-IEA-  
GO:0061590calcium activated phosphatidylcholine scrambling-IEA-  
GO:0061591calcium activated galactosylceramide scrambling-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-2672351Stimuli-sensing channelsTAS
R-HSA-382551Transport of small moleculesTAS
R-HSA-983712Ion channel transportTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal